The Telix Pharmaceuticals Ltd (ASX: TLX) share price is in focus today after the company announced a major collaboration with US-based Regeneron Pharmaceuticals, highlighted by a US$40 million upfront payment and the development of next-generation radiopharmaceuticals for cancer treatment.
Image source: Getty Images
What did Telix Pharmaceuticals report?
- Entered a 50/50 global cost and profit-sharing agreement with Regeneron to co-develop radiopharmaceutical therapies targeting solid tumours.
- Receives a US$40 million upfront cash payment for four initial therapeutic programs, with the option for Regeneron to expand to four more programs.
- Potential to earn up to US$2.1 billion in development and commercial milestone payments plus low double-digit royalties if Telix opts out of co-funding any program.
- Joint development of diagnostic assets, with Telix leading commercialisation and Regeneron receiving a percentage of profits.
- Collaboration leverages Telix's expertise in radiopharmaceuticals and Regeneron's proprietary antibody platforms.
What else do investors need to know?
This collaboration brings together Telix's strong track record in radiopharmaceutical manufacturing and Regeneron's experience in antibody discovery and oncology. The combined expertise could help accelerate the development of innovative treatments for cancers with significant unmet needs, such as lung cancer.
The partnership also includes plans to create radio-diagnostic tools, supporting both targeted therapies and patient selection for optimal outcomes. Telix retains some flexibility to promote products and can choose its level of involvement for each program, potentially switching between co-funding or milestone- and royalty-based compensation.
What did Telix Pharmaceuticals management say?
Managing Director and Group CEO Christian Behrenbruch said:
The collaboration with Regeneron reflects a highly complementary set of capabilities and a unique opportunity to explore what true 'next gen' biologics-based radiopharmaceuticals can potentially do for patients.
What's next for Telix Pharmaceuticals?
Telix and Regeneron will begin work on the first four programs under their collaboration, initially focusing on solid tumour targets from Regeneron's antibody pipeline. Further expansion is possible if milestones are met and both parties exercise their program options.
Telix's ability to co-develop diagnostics and therapies with Regeneron could set the stage for new approaches in precision oncology while expanding its global reach and product portfolio. Investors will be watching for progress updates and future milestones as the partnership unfolds.
Telix Pharmaceuticals share price snapshot
Over the past 12 months, Telix shares have declined 44%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 16% over the same period.
